Abstract
Despite the recent introduction of novel anti-multiple myeloma (MM) agents, high risk MM continues to have poor prognosis and remains a therapeutic challenge. Elotuzumab (ELO) is a humanized monoclonal antibody that recognizes SLAMF7, a molecule highly expressed on MM cells. The addition of ELO to lenalidomide (LEN) and dexamethasone (DEX) improved overall response rates and progression-free survival among patients (pts) with relapsed/refractory (RR) MM. The FDA has also approved ELO in combination with pomalidomide (POM) and low-dose DEX for the treatment of pts with RRMM following 2 or more prior therapies.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call